Scholarlink

<p>Clinical evidence of traditional Chinese medicine Tongxinluo capsule therapy on coronary plaque vulnerability is lacking. To investigate whether Tongxinluo may increase coronary plaque stability in patients admitted with acute coronary syndrome based on statin therapy, the TXL-CAP study, a multicenter, randomized, double-blind clinical trial, was conducted. Patients who had a coronary thin-cap lipid-rich plaque detected by optical coherence tomography (OCT) were randomized 1:1 to either Tongxinluo or placebo treatment for 12 months on the basis of guideline-directed treatment. The primary endpoint was the difference in the minimum fibrous cap thickness of the OCT-assessed lesions between Tongxinluo and placebo groups in patients at the end of 12 months. A total of 220 patients were finally recruited and randomized. For the primary endpoint, the minimum fibrous cap thickness did not differ between the two groups at baseline but increased in the Tongxinluo group relative to the placebo group at the 12-month follow-up (115.0 μm vs. 80.0 μm, <i>P</i> &lt; 0.001). The increase in the minimum fibrous cap thickness (61.2 μm vs. 33.7 μm, <i>P</i> = 0.002) and the decrease in the maximum lipid arc (−38.4° vs. −8.1°, <i>P</i> = 0.007) were greater in the Tongxinluo group than in the placebo group. The Tongxinluo group showed improvement in both the Seattle Angina Questionnaire score and the Canadian Cardiovascular Society grading of angina pectoris compared to the placebo group. In conclusion, on the basis of statins, Tongxinluo increased fibrous cap thickness, reduced the lipid arc of coronary thin-cap lipid-rich plaques, and improved angina symptoms without lowering cardiovascular events at the 12-month follow-up in patients with acute coronary syndrome. (<a href="http://www.chictr.org.cn">http://www.chictr.org.cn</a>, ID: ChiCTR1900025842).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月24日

查看全文
  • Mei Ni,
  • Yun Ti,
  • Huai Yu,
  • Meng Zhang,
  • Yan Qi,
  • Dayue Darrel Duan,
  • Qiang Xie,
  • Zheng Ji,
  • Ranzun Zhao,
  • Yujie Zhou,
  • Shaoliang Chen,
  • Lin Wang,
  • Yaojun Zhang,
  • Jincheng Guo,
  • Yuquan He,
  • Chen Yao,
  • Peili Bu,
  • Bo Yu,
  • Yun Zhang,
  • Cheng Zhang,
  • Peili Bu,
  • Xi Su,
  • Jianqiang Peng,
  • Bo Zhang,
  • Jun Xiao,
  • Zengming Xue,
  • Jianhong Tao

摘要

Clinical evidence of traditional Chinese medicine Tongxinluo capsule therapy on coronary plaque vulnerability is lacking. To investigate whether Tongxinluo may increase coronary plaque stability in patients admitted with acute coronary syndrome based on statin therapy, the TXL-CAP study, a multicenter, randomized, double-blind clinical trial, was conducted. Patients who had a coronary thin-cap lipid-rich plaque detected by optical coherence tomography (OCT) were randomized 1:1 to either Tongxinluo or placebo treatment for 12 months on the basis of guideline-directed treatment. The primary endpoint was the difference in the minimum fibrous cap thickness of the OCT-assessed lesions between Tongxinluo and placebo groups in patients at the end of 12 months. A total of 220 patients were finally recruited and randomized. For the primary endpoint, the minimum fibrous cap thickness did not differ between the two groups at baseline but increased in the Tongxinluo group relative to the placebo group at the 12-month follow-up (115.0 μm vs. 80.0 μm, P < 0.001). The increase in the minimum fibrous cap thickness (61.2 μm vs. 33.7 μm, P = 0.002) and the decrease in the maximum lipid arc (−38.4° vs. −8.1°, P = 0.007) were greater in the Tongxinluo group than in the placebo group. The Tongxinluo group showed improvement in both the Seattle Angina Questionnaire score and the Canadian Cardiovascular Society grading of angina pectoris compared to the placebo group. In conclusion, on the basis of statins, Tongxinluo increased fibrous cap thickness, reduced the lipid arc of coronary thin-cap lipid-rich plaques, and improved angina symptoms without lowering cardiovascular events at the 12-month follow-up in patients with acute coronary syndrome. (http://www.chictr.org.cn, ID: ChiCTR1900025842).